BLA 761312 · Citius Pharms
Lymphir
Denileukin Diftitox-Cxdl · Injection · CD25-directed Cytotoxin
OrphanLast checked: Nov 20, 2026Latest source record: Aug 7, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Aug 7, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
48
0 Phase 3, 3 recruiting
FAERS reports
10
8 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CAPILLARY LEAK SYNDROME Capillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients for signs and symptoms of CLS during treatment. Withhold LYMPHIR until CLS resolves, or permanently discontinue based on severity [see Dosage and Administration ( 2.1 , 2.4 ) and Warnings and Precautions ( 5.1 )] . WARNING: CAPILLARY LEAK SYNDROME See full prescribing information for complete boxed warning. Capillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients for signs and symptoms of CLS during treatment. Withhold LYMPHIR until CLS resolves or permanently discontinue based on severity. ( 2.1 , 2.4 , 5.1 )
What it is approved for
From the label in effect Jan 23, 2025.
LYMPHIR is indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. LYMPHIR is an IL2-receptor-directed cytotoxin indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. ( 1 )
Mechanism: Denileukin diftitox-cxdl is a fusion protein designed to direct the cytocidal action of diphtheria toxin (DT) to cells which express the IL-2 receptor. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a direct cytocidal action on IL-2R-expressing tumors.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 7, 2024 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLabelLetterReview
1 products under this application
- LYMPHIR · DENILEUKIN DIFTITOX-CXDL 300MCG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Denileukin Diftitox" as an intervention, any sponsor and status, largest first.
- Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) PatientsPivotal-lookingCompleted
Eisai Inc.Eisai
NCT00050999 · 195 participants · Start Jun 1995 · Primary completion Sep 2006
Drug: ONTAK · For: Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Sezary Syndrome
Sites: Houston, Texas; Saint Leonard's, Australia; Westmead, Australia · 35 sites in all
- Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00224874 · 180 participants · Start Sep 2005 · Primary completion Jan 2009
Drug: Etanercept; Mycophenolate Mofetil and 2 more · For: Graft vs Host Disease; Immune System Disorders
Sites: Duarte, California; San Diego, California; Stanford, California · 19 sites in all
- Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma PatientsCompleted
Eisai Inc.Eisai
NCT00051012 · 86 participants · Start Sep 1995 · Primary completion Oct 2006
Drug: ONTAK · For: Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Sezary Syndrome
Sites: Houston, Texas; Saint Leonard's, Australia; Westmead, Australia · 34 sites in all
Eastern Cooperative Oncology GroupResearch network
NCT00003615 · 77 participants (planned) · Start May 20, 1999 · Primary completion Aug 2006
Drug: denileukin diftitox · For: Lymphoma
Sites: Chicago, Illinois; Boston, Massachusetts; Las Vegas, Nevada · 10 sites in all
Eisai Inc.Eisai
NCT01127451 · 75 participants · Start Jun 22, 2010 · Primary completion Apr 7, 2015
Drug: Denileukin diftitox · For: Stage IIIC Melanoma; Stage IV Melanoma
Sites: Encinitas, California; Los Angeles, California; Washington D.C., District of Columbia · 10 sites in all
James Graham Brown Cancer CenterAcademic, hospital or other
NCT00299689 · 69 participants · Start Mar 2006 · Primary completion Jan 2010
Drug: Denileukin diftitox · For: Malignant Melanoma
Sites: Louisville, Kentucky
Eisai Inc.Eisai
NCT00211198 · 60 participants · Start May 2001 · Primary completion Jan 2005
Drug: ONTAK (denileukin difitox, DAB389IL-2) · For: Lymphoma, T-Cell, Cutaneous
Sites: Duarte, California; New Haven, Connecticut; Iowa City, Iowa · 9 sites in all
Eisai Inc.Eisai
NCT00211276 · 50 participants (planned) · Start Mar 2005 · Primary completion Jan 2007
Drug: ONTAK (denileukin diftitox) · For: Lymphoma, B-Cell
Sites: Beverly Hills, California; Fountain Valley, California; Los Angeles, California · 12 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- capillary leak syndrome3
- hypoxia2
- sepsis2
- acute kidney injury1
- atrial fibrillation1
- blood albumin decreased1
- cognitive disorder1
- communication disorder1
- condition aggravated1
- death1
- disease progression1
- enterovirus infection1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 1 |
| 2026 | 9 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.
Foss FM, Kim YH, Prince HM, et al. · J Clin Oncol 2025 · Multicenter Study, Clinical Trial, Phase III
- Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sézary syndrome receiving placebo.
Prince HM, Duvic M, Martin A, et al. · J Am Acad Dermatol 2012 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome.
Prince HM, Martin AG, Olsen EA, et al. · Leuk Lymphoma 2013 · Clinical Trial, Multicenter Study
- Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
Dannull J, Su Z, Rizzieri D, et al. · J Clin Invest 2005 · Clinical Trial, Research Support, N.I.H., Extramural
- Interventions for mycosis fungoides.
Valipour A, Jäger M, Wu P, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control.
Grzywacz B, Moench L, McKenna D, et al. · J Immunother 2019 · Clinical Trial, Research Support, N.I.H., Extramural
Sponsor: Citius Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.